Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial is futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously disappointing, we decided to take a calculated risk on this program and with the carefully staged agreement, we have spent a total of $15 million, a relatively modest amount for a late Phase 3 asset addressing a large market opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain dedicated to advancing our development pipeline by making investments in future growth and continue to look for attractive late-stage in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a divis
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has ... and Freezers Market - Global Industry Analysis, Size, ... report to their offering. ... been segmented based on applications: hospitals, research laboratories, ... others segment includes applications of biomedical refrigerators and ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce that ... the U.S. FDA Center For Biologics Evaluation and Research ... conduct a clinical trial investigating the safety and feasibility ... and early male pattern baldness (androgenic alopecia). ... follows initial clinical work in Europe ...
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... , In a study to be published in the April ... University,s School of Engineering and Applied Science report their findings ... Pole, has affected the entire circulation of the Southern Hemisphere ... shown that the ozone hole is changing the atmospheric flow ...
... April 21, 2011 KellBenx, a biotechnology company focused ... genetic and inherited disorders, announced today that it has ... four investors –  three biotechnology venture capital groups and ... trial and laboratory testing of a new, minimally invasive ...
... University of California, Riverside,s Bourns College of Engineering ... work in nanotechnology that could have far-reaching impacts ... of electrical engineering and founding chair of a ... to receive the Pioneer of Nanotechnology Award for ...
Cached Biology Technology:Columbia engineering study links ozone hole to climate change all the way to the equator 2Columbia engineering study links ozone hole to climate change all the way to the equator 3Engineering professor wins award for pioneering work expected to improve electronic devices 2
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... alumnus) Hudi Benayahu, head of TAU,s Porter School of ... and important part of reef environments, are simply melting ... mean a global marine catastrophe. Environmental stress, says ... and the microscopic symbiotic algae living in their tissues. ...
... vaccine be the key to stopping Alzheimers disease" A ... (OMRF) shows that immunization could offer a way to ... OMRF scientists immunized Alzheimers mice with a protein believed ... The mice who received the vaccination showed a significant ...
... the European Molecular Biology Laboratory [EMBL] announces Luxembourg ... Accepted by EMBL,s council and ratified by the ... the institute as the 20th member state. ... biology," says Franois Biltgen, Minister of Culture, Higher ...
Cached Biology News:TAU professor finds global warming is melting soft coral 2An Alzheimer's vaccine? 2An Alzheimer's vaccine? 3Luxembourg joins EMBL 2
... Anti-Clusterin α chain (human), clone 41D ... Immunogen : Native clusterin purified ... pH 7.4, 0.15M NaCl and 0.05% ... on RIPA lysates from HeLa cells ...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Chlamydia pneumoniae (TWAR)...
Mouse anti-Insulin-Like-3 Class: Antibody Product Group: Adipokine and Obesity related...
Biology Products: